Valuation: Valneva SE

Market Cap 400M 456M 372M 342M 642M 43.9B 652M 4.42B 1.73B 21.58B 1.71B 1.67B 74.62B P/E 2026 *
-5.75x
P/E 2027 * 5.56x
Enterprise Value 528M 602M 491M 451M 847M 57.93B 860M 5.83B 2.28B 28.48B 2.26B 2.21B 98.47B EV / Sales 2026 *
3.48x
EV / Sales 2027 * 1.57x
Free-Float
97.36%
Yield 2026 *
-
Yield 2027 * -
1 day+1.34%
1 week-2.09%
Current month-6.39%
1 month-5.42%
3 months-8.81%
6 months-46.09%
Current year-43.22%
1 week 2.03
Extreme 2.033
2.17
1 month 2.03
Extreme 2.033
2.37
Current year 2.03
Extreme 2.033
5.15
1 year 2.03
Extreme 2.033
5.42
3 years 1.73
Extreme 1.726
7.17
5 years 1.73
Extreme 1.726
29.7
10 years 1.73
Extreme 1.726
29.7
Manager TitleAgeSince
Chief Executive Officer 62 -
Director of Finance/CFO 56 28/07/2021
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Director/Board Member 62 19/12/2023
Director/Board Member 75 06/03/2013
Chairman 65 19/12/2023
Date Insider Type Main position Quantity % Market Cap.
27/01/26 Sell

Chief Technology Officer

11,800 0.0069%
26/01/26 Sell

Chief Financial Officer

11,800 0.0069%
19/01/26 Sell

Chief Operating Officer

6,206 0.0036%
Change 5-day change 1-year change 3-year change Capi.($)
+1.34%-2.09%-34.81%-68.73% 456M
+1.07%-3.49%-3.35%+11.75% 46.86B
+0.25%+1.65%+399.22%+647.65% 40.23B
-0.27%+4.45%+11.81%+60.81% 36.23B
+0.35%+0.87%+4.46%-10.31% 34.72B
+3.14%+1.02%+4.76%+43.00% 27.89B
-0.73%+11.84%+34.39%+134.44% 16.79B
+0.47%-2.74% - - 16.74B
+0.42%-5.52%-3.43%+9.10% 13.12B
-2.68%-2.49%-11.36%-34.51% 12.7B
Average +0.34%+0.54%+44.63%+88.13% 24.57B
Weighted average by Cap. +0.48%+0.91%+74.20%+137.80%

Financials

2026 *2027 *
Net sales 152M 173M 141M 130M 243M 16.65B 247M 1.68B 655M 8.18B 649M 635M 28.3B 294M 335M 273M 251M 471M 32.24B 479M 3.25B 1.27B 15.85B 1.26B 1.23B 54.8B
Net income -66.01M -75.16M -61.39M -56.33M -106M -7.24B -107M -729M -285M -3.56B -282M -276M -12.3B 70.5M 80.27M 65.56M 60.16M 113M 7.73B 115M 779M 304M 3.8B 301M 295M 13.14B
Net Debt 128M 146M 119M 109M 205M 14.04B 208M 1.41B 552M 6.9B 547M 535M 23.86B 60.02M 68.33M 55.81M 51.22M 96.23M 6.58B 97.72M 663M 259M 3.24B 257M 251M 11.19B
Logo Valneva SE
Valneva is a specialty vaccine company that develops, manufactures, and commercializes prophylactic vaccines for infectious diseases addressing unmet medical needs. Valneva takes a highly specialized and targeted approach, applying its deep expertise across multiple vaccine modalities, focused on providing either first-, best- or only-in-class vaccine solutions. Valneva has a strong track record, having advanced multiple vaccines from early R&D to approvals, and currently markets three proprietary travel vaccines. Revenues from its growing commercial business help fuel the continued advancement of its vaccine pipeline. This includes the only Lyme disease vaccine candidate in advanced clinical development, which is partnered with Pfizer, the world's most clinically advanced Shigella vaccine candidate, as well as vaccine candidates against other global public health threats.
Employees
674
Date Price Change Volume
24/07/26 €2.111 +1.34% 666,618
23/07/26 €2.083 -2.75% 341,334
22/07/26 €2.142 +0.47% 322,589
21/07/26 €2.132 +0.09% 353,577
20/07/26 €2.130 -1.21% 307,404
Trader
Investor
Global
Quality
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
2.111EUR
Average target price
5.233EUR
Spread / Average Target
+147.91%

Quarterly revenue - Rate of surprise